ID
37356
Beschreibung
Study ID: 111592 Clinical Study ID: 111592 Study Title: A Randomized, Double-blind, Placebo-controlled, Doseescalation Study to Assess the Anti-inflammatory Activity, Efficacy, and Safety of Intravenous SB-681323 in Subjects at Risk for Development of Acute Lung Injury or ARDS Patient Level Data: Study Listed on ClinicalStudyDataRequest.com Clinicaltrials.gov Identifier: NCT00996840 See https://clinicaltrials.gov/ct2/show/NCT00996840 Sponsor: GlaxoSmithKline Collaborators: N/A Phase: Phase 2 Study Recruitment Status: Completed Generic Name: Placebo, SB-681323 Trade Name: N/A Study Indication: Lung Injury, Acute The primary objective of this phase 2 trial is to evaluate the safety and tolerability of intravenous dilmapimod/SB-681323 given in escalating dosages and over different intervals for three days in trauma patients at risk for the development of ALI or ARDS. This study consists of Screening, infusion of dilmapimod/SB-681323 on days 1-3, examination/sampling up to early day 5 (denoted as "Day 3 - 48 hrs") and a Follow-up on day 7. There are four cohorts, cohorts 1 and 3 receive the medication (or placebo) infusion over 4 hours, cohorts 2 and 4 over 24 hours. This form is to be filled in continously during the study and/or at the follow-up evaluation and contains information on other medication the participant has received during the course of the study.
Link
https://clinicaltrials.gov/ct2/show/NCT00996840
Stichworte
Versionen (1)
- 20.07.19 20.07.19 -
Rechteinhaber
GlaxoSmithKline
Hochgeladen am
20. Juli 2019
DOI
Für eine Beantragung loggen Sie sich ein.
Lizenz
Creative Commons BY-NC 3.0
Modell Kommentare :
Hier können Sie das Modell kommentieren. Über die Sprechblasen an den Itemgruppen und Items können Sie diese spezifisch kommentieren.
Itemgroup Kommentare für :
Item Kommentare für :
Um Formulare herunterzuladen müssen Sie angemeldet sein. Bitte loggen Sie sich ein oder registrieren Sie sich kostenlos.
SB-681323 in ALI/ARDS risk patients - NCT00996840
Concomitant Medications
- StudyEvent: ODM
Beschreibung
Concomitant Medications
Alias
- UMLS CUI-1
- C2347852
Beschreibung
Sequence Number
Datentyp
text
Alias
- UMLS CUI [1]
- C2348184
Beschreibung
Trade Name preferred
Datentyp
text
Alias
- UMLS CUI [1]
- C2360065
Beschreibung
[hidden]
Datentyp
text
Alias
- UMLS CUI [1]
- C2826819
Beschreibung
[hidden]
Datentyp
text
Alias
- UMLS CUI [1,1]
- C0013227
- UMLS CUI [1,2]
- C0871468
Beschreibung
[hidden]
Datentyp
text
Alias
- UMLS CUI [1,1]
- C0013227
- UMLS CUI [1,2]
- C1516698
- UMLS CUI [1,3]
- C0805701
Beschreibung
[hidden]
Datentyp
boolean
Alias
- UMLS CUI [1,1]
- C0805701
- UMLS CUI [1,2]
- C0231175
Beschreibung
Unit Dose
Datentyp
text
Alias
- UMLS CUI [1]
- C0869039
Beschreibung
Concomitant Medication Units
Datentyp
integer
Alias
- UMLS CUI [1,1]
- C1519795
- UMLS CUI [1,2]
- C2347852
Beschreibung
Concomitant Medication Frequency
Datentyp
text
Alias
- UMLS CUI [1,1]
- C3476109
- UMLS CUI [1,2]
- C2347852
Beschreibung
Concomitant Medication Route
Datentyp
text
Alias
- UMLS CUI [1,1]
- C0013153
- UMLS CUI [1,2]
- C2347852
Beschreibung
Reason for Medication
Datentyp
text
Alias
- UMLS CUI [1,1]
- C0392360
- UMLS CUI [1,2]
- C0013227
Beschreibung
Start Date and Time
Datentyp
datetime
Alias
- UMLS CUI [1]
- C3897500
Beschreibung
Concomitant Medication Taken Prior to Study?
Datentyp
boolean
Alias
- UMLS CUI [1]
- C2826667
Beschreibung
If no, specify End Date and Time
Datentyp
boolean
Alias
- UMLS CUI [1]
- C2826666
Beschreibung
End date and time
Datentyp
datetime
Alias
- UMLS CUI [1]
- C3899266
Ähnliche Modelle
Concomitant Medications
- StudyEvent: ODM
C1264639 (UMLS CUI [1,2])
C0871468 (UMLS CUI [1,2])
C1516698 (UMLS CUI [1,2])
C0805701 (UMLS CUI [1,3])
C0231175 (UMLS CUI [1,2])
C2347852 (UMLS CUI [1,2])
C2347852 (UMLS CUI [1,2])
C0013227 (UMLS CUI [1,2])